Mometasone Teva (Mometasone Furoate)

Mometasone furoate, the active ingredient in Mometasone Teva, is a corticosteroid presented as a nasal spray for nasal administration. It is used to treat inflammatory nasal conditions such as allergic rhinitis and nasal polyps in adults and children.

GNH USA supplies Mometasone Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mometasone Teva is a nasal corticosteroid that reduces inflammation in the upper airway. It is indicated for several ENT conditions: - Allergic rhinitis: relieves nasal congestion, itching, and sneezing caused by allergens. - Nasal polyps: decreases polyp size and improves nasal airflow. - Nasal congestion due to inflammation: reduces swelling of the nasal mucosa to facilitate breathing.

Mometasone Teva may cause local and systemic adverse reactions.

Common Side Effects: - Nasal irritation or burning sensation. - Headache. - Epistaxis (nosebleed). - Throat irritation or dryness. - Cough. - Altered taste or bitter taste.

Serious or Rare Side Effects: - Nasal septal perforation. - Severe allergic reaction (anaphylaxis). - Visual disturbances or increased intra‑ocular pressure. - Adrenal suppression with prolonged high‑dose use. - Opportunistic fungal infection of the nasal passages.

Before using Mometasone Teva, consider the following safety measures: - Prescription only: use under medical supervision. - Active infection: avoid if nasal or sinus infection is present. - Children: use the lowest effective dose and monitor growth. - Ocular pressure: monitor for signs of glaucoma or cataract formation. - Discontinuation: taper gradually after long‑term therapy to prevent adrenal insufficiency. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Mometasone Teva can interact with other medicines that affect corticosteroid metabolism or increase systemic exposure.

Major Interactions (Avoid): - Systemic corticosteroids: may increase risk of systemic glucocorticoid effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise local drug levels.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may modestly increase exposure. - Antihistamines: may enhance sedative effects when combined with other CNS depressants. - Antiviral protease inhibitors (e.g., ritonavir): monitor for increased local irritation.